MedTrace Logo

Opioid and Cannabinoid Interactions

NCT03705559 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

This study will examine the effects of doses of marijuana/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.

Conditions

  • Marijuana Usage
  • Opioid Use

Interventions

DRUG

Vaporized Marijuana

Active Marijuana administered through vaporizer

DRUG

Opioid Agonist

Active Opioid Agonist administered intranasally

DRUG

Placebo

Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Shanna Babalonis, PhD

    lead OTHER

Principal Investigators

  • Shanna Babalonis, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-21
Primary Completion
2024-02-15
Completion
2024-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03705559 on ClinicalTrials.gov